People's Health Press
ISSN 2096-2738 CN 11-9370/R
  • Official WeChat

  • Official Weibo

  • Official headlines

Electronic Journal of Emerging Infectious Diseases ›› 2022, Vol. 7 ›› Issue (4): 12-15.doi: 10.19871/j.cnki.xfcrbzz.2022.04.003

• Original Articles • Previous Articles     Next Articles

Analysis of drug resistance and comorbidity in 6765 patients with culture positive pulmonary tuberculosis

Li Tongxia1, Chu Yan2, Lin Mei1, Li Jing1, Wang Bingrui3, Ma Guangren2   

  1. 1. Tuberculosis Department of Qingdao Chest Hospital, Shandong Qingdao 266000, China;
    2. Laboratory Department of Qingdao Chest Hospital, Shandong Qingdao 266000, China;
    3. Department of laboratory, Central Health Center, Shejia Town, Wudi County, Shandong Binzhou 251903, China
  • Received:2022-05-24 Published:2023-02-20

Abstract: Objective To investigate the drug resistance and comorbidity of pulmonary tuberculosis patients in Qingdao, and provide scientific basis for the prevention and control of tuberculosis and the management of drug-resistant tuberculosis. Method A retrospective study was conducted on the relevant with pulmonary tuberculosis diagnosed clinically in or out of the Qingdao Thoracic Hospital from September 2016 to March 2021. The sputum smear and culture of the patients with sputum or alveolar lavage fluid were positive. At the same time, the laboratory drug sensitivity test was carried out. According to the test results, 6765 patients with pulmonary tuberculosis diagnosed were divided into multi drug/rifampicin resistant group and drug sensitive pulmonary tuberculosis as the control group. The Charlson comorbidity index (CCI) of the two groups was calculated, The drug resistance related factors and comorbidity of the two groups were analyzed. Result Which 346 cases were multidrug/rifampicin resistant and 6419 cases were drug sensitive pulmonary tuberculosis. Drug resistance of pulmonary tuberculosis patients and classification of tuberculosis treatment history(χ2=47.165, P<0.001), age(χ2=62.531, P<0.001), region(χ2=12.671, P<0.001) and high comorbidity(χ2=20.983,P<0.001); MDR/rifampicin resistant patients in rural areas are more likely to be complicated with high comorbidities.The incidence of diabetes from high to low was diabetes, hypertension, pulmonary heart disease, mental illness, malignant tumors and HIV infection. Multidrug resistant/rifampicin resistant combinations were higher than those of non resistant groups in diabetes(χ2=20.142,P<0.001), mental disorders(χ2=6.266, P=0.012), malignant tumors(χ2=6.266, P=0.012) and HIV infection(χ2=4.335, P=0.037). Conclusion The high risk factors of MDR/rifampicin resistant pulmonary tuberculosis are retreatment, rural areas, aging and high comorbidity. The proportion of high comorbidity in MDR/rifampicin resistant pulmonary tuberculosis patients is higher than that in the control group. We should strengthen the intervention of high comorbidity patients, so as to improve the cure rate of MDR patients.

Key words: Pulmonary tuberculosis, Mycobacterium tuberculosis, Drug resistance, Comorbidity